1. Scrip
  2. >>Therapy Areas

Valeant's Dermatology Sales Strategy: Teenage Zits

 
• By Donna Young

Valeant Pharmaceutical International Inc.'s dermatology business is in trouble. But CEO Joseph Papa said the company is counting on teenagers eager to have clear skin when they return to school in the fall to boost prescriptions of the firm's acne medicine Solodyn (minocycline).

Valeant Pharmaceuticals International Inc. is counting on teenagers' back-to-school skin concerns to help boost the company's profits in the second half of this year and save its dermatology business, which had a 55% decline in revenues in the second quarter from the same period a year ago.

"As many of the teenagers go back to school, that's an important time period for acne and other parts of the dermatology franchise," Valeant CEO Joseph Papa told investors and analysts during the company's Aug. 9 second-quarter earnings conference call

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.